Bayer's pharma president and board member Dieter Weinand talks to Scrip about the importance of big picture thinking when weighing the value of innovative drugs to healthcare systems, the revolutionary potential of big data and how "transparency and open dialogue will further enhance the understanding of our business."
Sanofi's chief scientific officer Gary Nabel, who joined the company in 2012 from the NIH, discusses R&D challenges for Sanofi and the wider pharma industry, and highlights the company's biggest drug development achievements and toughest moments over the last few years.
Gary Dubin, senior vice president and global medical officer in Takeda Pharmaceutical Co.’s Vaccine Business Unit, talks about the trials and tribulations of vaccine R&D and how it felt to get one of the world's first human papillomavirus injections to market.
When it was announced in September that Novartis's chief medical officer Vas Narashimhan is going to replace Joseph Jimenez as the Swiss major's chief executive in February 2018, much was made of the fact that one of the world's biggest pharmaceutical companies will be led by a scientist.
MassBio and Liftstream partnered on a report about women's, men's and companies' views on gender diversity in the life science industry and identified several opportunities for employers to improve, including the need to employ more women in leadership roles to attract female job-seekers.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.